Macrocyclics

Macrocyclics specializes in the development and manufacture of customized chelating agents critical to diagnostic and therapeutic medicine. Their products are widely used in nuclear medicine—especially molecular imaging—and they provide cGMP manufacturing services supporting clinical trials. The company’s technology enables site-specific bioconjugation of radionuclides to biomolecules such as monoclonal antibodies or peptides. They do not develop therapeutics themselves but are an essential partner/supplier in the field of radiopharmaceutical development and advanced diagnostics. Since acquisition by Orano Med in 2011, Macrocyclics has expanded its capabilities with state-of-the-art chemistry/radiochemistry labs supporting both research-grade and GMP production needs.